Matthew D Galsky

I'm going to give both.

But also Matt Galsky is going to need to answer that question in exactly two weeks time.

So because the reason why I want Matt to address and Jonathan and others and sure is that.

If we are curing the majority of patients or putting them into a clinical CR, which I think is probably going to be 60% of people, if that is the case, what are we irradiating? Is it just normal bladder? And so, again, this unselected approach, and by the way, I'm a fan of radiation therapy.

So is this a possibility here? Are we getting closer to biology-driven treatment selection in muscle invasive bladder cancer? Because maybe not all of the patients, like in the B15, where 90% of the patients are pure urothelial, and you've done a lot of great work here in terms of the variant histology.

So what are your thoughts about Dr. Galsky's presentation, Petros, in terms of the molecular subtypes from the Niagara?

Great presentation, great work.

And I always applaud the investigators and groups and research teams for doing this work.

On the flip side, you know, patients who remain positive after cystectomy, their outcome is very poor.

We need urgently trials, right, in post-cystectomy positive CDNA status.

And there are trials, for example, Modern Trial with Dr. Galsky and Alliance, the Tropion 04 trial with...

A different trope to ADC, plus minus immunotherapy versus standard of care control.